Glucose Health, Inc.
0.1310+0.03 (+24.8%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · GLUC · USD
Key Stats
Market Cap
2.28MP/E (TTM)
-Basic EPS (TTM)
-0.03Dividend Yield
0%Recent Filings
10-Q
Q3 FY2017 results
Glucose Health swung to profitability in Q3 2017 ended September 30, with revenue climbing to $23,783 from $2,110 a year earlier, while gross profit hit $22,993 versus a $2,624 loss, thanks to stronger Walmart orders that make up 99% of sales. Operating income turned positive at $4,635 from a $55,556 loss, and net income reached $18,769 or $0.00 per share on 4,148,101 diluted shares, up from a $160,819 loss or $(0.06) per share—yet YTD revenue dipped to $72,940 from $298,039, yielding $39,018 net income or $0.01 per share. Cash drained to $16,636 amid $13,906 operating outflow, with total debt at $332,877 including $112,157 related-party convertible notes at 5%; a May settlement slashed payables by $38,277. No free cash flow disclosed in the 10-Q. Shares outstanding ballooned to 4,515,810 via conversions. Customer concentration risks loom large.
10-Q
Q2 FY2017 results
Glucose Health swung to profitability in Q2 FY2017 ended June 30, 2017, posting net income of $49,258, up from a $87,370 loss a year earlier, driven by a $38,277 gain on accounts payable settlement that offset $5,096 interest expense—far below the prior year's $93,402 hit from note discount amortization. Revenue dipped sharply to $34,046 from $295,809 year-over-year, yet gross profit climbed to $33,774 on lower costs, yielding operating income of $16,077 versus $6,032; six-month figures show $49,157 revenue and $20,249 net income against last year's $295,929 and $125,544 loss. Cash stood at $18,313 with operating cash use of $12,229, propped by $10,000 net financing inflows amid $476,607 total debt including $112,157 related-party convertibles at 5%. Shares outstanding hit 3,979,792, aligning with $0.01 diluted EPS on 3,718,155 weighted average. No free cash flow disclosed in the 10-Q. Reliance on Walmart for 100% of sales exposes the firm to retailer concentration risks.
10-Q
Q1 FY2017 results
Glucose Health posted Q1 revenue of $15,111, up sharply from $120 a year ago, yet gross profit stayed slim at $473 while operating expenses climbed 133% to $28,786 on higher professional fees and advertising. That drove an operating loss of $28,313, widening from $12,275, with net loss steady at $29,009 or $0.01 per diluted share on 3,341,930 weighted shares—interest expense dropped to $696 from $16,988, keeping the bottom line flat. Cash burned $11,534 to end at $9,008, with no capex so free cash flow matched operating outflow; total debt held at $350,977 including related-party notes at 24% and convertibles at 5%, revolver not disclosed in the 10-Q. Revenue hinges on Walmart, now stocking the product nationwide. Cash is tight.
8-K
Auditor switch announced
Glucose Health, Inc. switched auditors on April 6, 2017, as Anton & Chia, LLP declined reelection for the 2017 fiscal period, prompting the board to engage Michael Gillespie & Associates, PLLC. No disagreements arose on accounting principles, disclosures, or audit scope during 2015-2016, and prior reports carried only a going-concern explanatory paragraph. The clean transition underscores steady financial reporting. Yet, the going-concern note lingers.
10-K
FY2016 results
Glucose Health posted FY2016 revenue of $313,229, up sharply from $4,272 in 2015, driven by Walmart stocking its Glucose Health® tea mix in most pharmacies nationwide by year-end. Gross profit hit $19,167, yet operating expenses fell 32% to $105,814, trimming the operating loss to $86,647—still a net loss of $410,443 or $0.15 per diluted share on 2.8 million shares, with $324K of the shortfall tied to interest and debt discount amortization. Q4 momentum surged via a Citibank receivables deal accelerating Walmart payments, boosting cash to $20,542 from $2,055 yearly, while accounts receivable climbed to $11,724. No dividends or buybacks; related-party notes funded operations amid a $496K working capital deficit. No annual guidance disclosed. Intense competition from giants like Abbott and Nestle threatens quarterly sales ramps.
IPO
Sector
Industry
BFNH
BioForce Nanosciences Holdings,
0.80+0.00
BHST
BioHarvest Sciences Inc.
9.84-0.14
GWLL
GOLDENWELL BIOTECH INC
6.00+3.30
HCWC
Healthy Choice Wellness Corp.
0.64-0.01
INGR
Ingredion Incorporated
115.71-1.91
NATR
Nature's Sunshine Products, Inc
13.42-0.43
RKDA
Arcadia Biosciences, Inc.
3.71-0.07
USNA
USANA Health Sciences, Inc.
19.61-0.72
WEST
Westrock Coffee Company
4.77-0.24
ZVIA
Zevia PBC
2.37-0.07